Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze & Stephen N. Davis. (2019) Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in
the treatment of diabetic kidney disease. Expert Opinion on Investigational Drugs 28:4, pages 377-388.
Read now
Read now
Eva W Iepsen, Signe S Torekov & Jens J Holst. (2014) Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opinion on Pharmacotherapy 15:17, pages 2487-2500.
Read now
Read now
Bo Ahrén. (2008) Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular Health and Risk Management 4:2, pages 383-394.
Read now
Read now
Articles from other publishers (41)
Amisha Bisht, Disha Tewari, Sanjay Kumar & Subhash Chandra. (2023) Network pharmacology, molecular docking, and molecular dynamics simulation to elucidate the mechanism of anti-aging action of Tinospora cordifolia. Molecular Diversity.
Crossref
Crossref
Małgorzata Trocha, Małgorzata Krzystek-Korpacka, Anna Merwid-Ląd, Beata Nowak, Małgorzata Pieśniewska, Piotr Dzięgiel, Agnieszka Gomułkiewicz, Przemysław Kowalski, Dorota Diakowska, Adam Szeląg & Tomasz Sozański. (2019) Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion. Oxidative Medicine and Cellular Longevity 2019, pages 1-10.
Crossref
Crossref
Carina Proença, Marisa Freitas, Daniela Ribeiro, Sara M. Tomé, Alberto N. Araújo, Artur M. S. Silva, Pedro A. Fernandes & Eduarda Fernandes. (2019) The dipeptidyl peptidase-4 inhibitory effect of flavonoids is hindered in protein rich environments. Food & Function 10:9, pages 5718-5731.
Crossref
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Crossref
Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A. Abbott, Emma Parkinson-Lawrence, Douglas A. Brooks & Ross N. Butler. (2019) Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity. Scientific Reports 9:1.
Crossref
Crossref
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2018) Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes, Obesity and Metabolism 20:3, pages 530-540.
Crossref
Crossref
Andrew J. Krentz & Alan J. Sinclair. 2017. Diabetes in Old Age. Diabetes in Old Age
298
322
.
Yang Liu & Yongzhou Hu. (2014) Novel DPP-4 inhibitors against diabetes. Future Medicinal Chemistry 6:7, pages 793-808.
Crossref
Crossref
Derek J. Nunez, Mark A. Bush, David A. Collins, Susan L. McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow & Paul L. Feldman. (2014) Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies. PLoS ONE 9:4, pages e92494.
Crossref
Crossref
Bianca Hemmeryckx, Melissa Swinnen, David J Gallacher, Hua Rong Lu & H. Roger Lijnen. (2014) Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice. European Journal of Pharmacology 723, pages 175-180.
Crossref
Crossref
M. Alba, B. Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman & B. J. Goldstein. (2013) Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes, Obesity and Metabolism 15:12, pages 1101-1110.
Crossref
Crossref
L. Ohlsson, W. Alsalim, R. D. Carr, A. Tura, G. Pacini, A. Mari & B. Ahrén. (2013) Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes, Obesity and Metabolism 15:6, pages 531-537.
Crossref
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Crossref
Jens Juul Holst & Carolyn F. Deacon. (2013) Is there a place for incretin therapies in obesity and prediabetes?. Trends in Endocrinology & Metabolism 24:3, pages 145-152.
Crossref
Crossref
Cui Wei, Liang Desheng, Gao Jian, Luo Fang, Geng Lingling & Ji Mingjuan. (2012) Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV. Journal of Molecular Modeling 19:3, pages 1167-1177.
Crossref
Crossref
Cui Li, Weiqiang Lu, Chunhua Lu, Wen Xiao, Xu Shen, Jin Huang, Guixia Liu & Yun Tang. (2012) Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening. Journal of Molecular Modeling 18:9, pages 4033-4042.
Crossref
Crossref
E N Arwert, R A Mentink, R R Driskell, E Hoste, S J Goldie, S Quist & F M Watt. (2011) Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene 31:8, pages 992-1000.
Crossref
Crossref
Jun Hou, Dezhi Zheng, Kaihua Fan, Botao Yu, Wenjing Xiao, Jie Ma, Weihua Jin, Yonghong Tan & Juan Wu. (2012) Combination of Mangiferin and Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Impaired Glucose Tolerance in Streptozotocin-Diabetic Rats. Pharmacology 90:3-4, pages 177-182.
Crossref
Crossref
Liang Desheng, Gao Jian, Cheng Yuanhua, Cui Wei, Zhang Huai & Ji Mingjuan. (2011) Molecular dynamics simulations and MM/GBSA methods to investigate binding mechanisms of aminomethylpyrimidine inhibitors with DPP-IV. Bioorganic & Medicinal Chemistry Letters 21:22, pages 6630-6635.
Crossref
Crossref
Juergen Sandow. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Su-Jin Kim, Cuilan Nian & Christopher H.S. McIntosh. (2011) Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation. Journal of Lipid Research 52:4, pages 759-770.
Crossref
Crossref
Ping Chen, Charles G. Caldwell, Wallace Ashton, Joseph K. Wu, Huaibing He, Kathryn A. Lyons, Nancy A. Thornberry & Ann E. Weber. (2011) Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters 21:6, pages 1880-1886.
Crossref
Crossref
Jitendra Vaghasiya, Navin Sheth, Yagnik Bhalodia & Ravi Manek. (2011) Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regulatory Peptides 166:1-3, pages 48-54.
Crossref
Crossref
Su-Jin Kim, Cuilan Nian & Christopher H.S. McIntosh. (2010) GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. Journal of Lipid Research 51:11, pages 3145-3157.
Crossref
Crossref
Scott D. Edmondson, Feng Xu & Joseph D. ArmstrongIIIIII. 2010. Modern Drug Synthesis. Modern Drug Synthesis
123
140
.
Teng-Kuang Yeh, Ting-Yueh Tsai, Tsu Hsu, Jai-Hong Cheng, Xin Chen, Jen-Shin Song, Horng-Shing Shy, Mei-Chun Chiou, Chia-Hui Chien, Ya-Ju Tseng, Chung-Yu Huang, Kai-Chia Yeh, Yu-Lin Huang, Chih-Hsiang Huang, Yu-Wen Huang, Min-Hsien Wang, Hung-Kuan Tang, Yu-Sheng Chao, Chiung-Tong Chen & Weir-Torn Jiaang. (2010) (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorganic & Medicinal Chemistry Letters 20:12, pages 3596-3600.
Crossref
Crossref
Sun Woo Kim. (2010) Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. Korean Diabetes Journal 34:6, pages 331.
Crossref
Crossref
James Mu, Aleksandr Petrov, George J. Eiermann, John Woods, Yun-Ping Zhou, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Ranabir Sinha Roy, Andrew D. Howard, Cai Li, Nancy A. Thornberry & Bei B. Zhang. (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European Journal of Pharmacology 623:1-3, pages 148-154.
Crossref
Crossref
Jia-Jing Wu, Hung-Kuan Tang, Teng-Kuang Yeh, Chi-Min Chen, Hrong-Shing Shy, Yue-Ru Chu, Chia-Hui Chien, Ting-Yueh Tsai, Yu-Chen Huang, Yu-Lin Huang, Chih-Hsiang Huang, Huan-Yi Tseng, Weir-Torn Jiaang, Yu-Sheng Chao & Xin Chen. (2009) Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochemical Pharmacology 78:2, pages 203-210.
Crossref
Crossref
Bo Ahrén. (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nature Reviews Drug Discovery 8:5, pages 369-385.
Crossref
Crossref
Ralph A. DeFronzo. (2009) From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 58:4, pages 773-795.
Crossref
Crossref
Ting-Yueh Tsai, Tsu Hsu, Chiung-Tong Chen, Jai-Hong Cheng, Mei-Chun Chiou, Chih-Hsiang Huang, Ya-Ju Tseng, Teng-Kuang Yeh, Chung-Yu Huang, Kai-Chia Yeh, Yu-Wen Huang, Ssu-Hui Wu, Min-Hsien Wang, Xin Chen, Yu-Sheng Chao & Weir-Torn Jiaang. (2009) Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters 19:7, pages 1908-1912.
Crossref
Crossref
E. V. Shlyakhto, E. N. Grineva, A. Yu. Babenko & A. V. Dronova. (2009) Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology. "Arterial’naya Gipertenziya" ("Arterial Hypertension") 15:1, pages 31-41.
Crossref
Crossref
Christopher H.S. McIntosh, Scott Widenmaier & Su‐Jin Kim. 2009. Insulin and IGFs. Insulin and IGFs
409
471
.
Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka & Hiroyuki Odaka. (2008) Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. European Journal of Pharmacology 588:2-3, pages 325-332.
Crossref
Crossref
John Doupis & Aristidis Veves. (2008) DPP4 Inhibitors: a new approach in diabetes treatment. Advances in Therapy 25:7, pages 627-643.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:2, pages 193-219.
Crossref
Crossref
Bo Ahrén. (2008) Vildagliptin: novel pharmacological approach to treat Type 2 diabetes. Therapy 5:1, pages 79-90.
Crossref
Crossref
Christopher H.S. McIntosh. (2008) Incretin-based Therapies for Type 2 Diabetes. Canadian Journal of Diabetes 32:2, pages 131-139.
Crossref
Crossref
Peggy Soule Odegard, Stephen M. Setter & Joshua J. Neumiller. (2007) Considerations for the Pharmacological Treatment of Diabetes in Older Adults. Diabetes Spectrum 20:4, pages 239-247.
Crossref
Crossref
Ying-Duo Gao, Dennis Feng, Robert P. Sheridan, Giovanna Scapin, Sangita B. Patel, Joseph K. Wu, Xiaoping Zhang, Ranabir Sinha-Roy, Nancy A. Thornberry, Ann E. Weber & Tesfaye Biftu. (2007) Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters 17:14, pages 3877-3879.
Crossref
Crossref